Bionomics Ltd.
OTCQB: BNOEF
Company Overview
Bionomics (ASX: BNO) (OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of clinical-stage ion channel programs targeting pain, depression, cognition and epilepsy.
Financial Highlights
$6,018,739
Revenue (ttm)
-$9,943,677
Gross Profit (ttm)
-$0.02
Diluted EPS (ttm)
Management Team
Dr. Errol B. De Souza Ph.D.
Exec. Chairman
Mr. Adrian Hinton BEC, F.C.A.
Acting Chief Financial Officer
Mr. Connor Bernstein M.Sc.
VP of Strategy & Corp. Devel.
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.
Consultant Chief Medical Officer of Clinical Neuroscience
Ms. Suzanne Irwin B.Com., FCIS
Company Sec.
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
()
Insider Ownership
7%